IL-17A Recombinant Rabbit mAb (SDT-892-36-2)

Interleukin-17 (IL-17, also known as IL-17A) is a key cytokine that links T cell activation to neutrophil mobilization and activation. As such, IL-17 can mediate protective innate immunity to pathogens or contribute to the pathogenesis of inflammatory diseases, such as psoriasis and rheumatoid arthritis. The current burden of evidence from human and animal model studies suggests that the net effect of IL-17 signaling promotes disease development. In addition to promoting neutrophilic inflammation, IL-17 has potent pro-osteoclastogenic effects that are likely to contribute to the pathogenesis of periodontitis, rheumatoid arthritis, and other diseases involving bone immunopathology. Systemic treatments with anti-IL-17 biologics have shown promising results in clinical trials for psoriasis and rheumatoid arthritis, although their impact on the highly prevalent periodontal disease has not been investigated or reported. Future clinical trials, preferably using locally administered IL-17 blockers, are required to conclusively implicate IL-17 in periodontitis and, more importantly, to establish an effective adjunctive treatment for this oral inflammatory disease. (PMID: 26252407)